Depression: all studies (page 71) - The Consciousness Library

Effectiveness of a Mindfulness-Based Mobile Intervention for Improving Perinatal Mental Health and Reducing Depression During Pregnancy: Randomized Controlled Trial.

Journal of Medical Internet Research October 2, 2025 Minjung Kim, Jin Young Park, Sehwan Park et al.

Background: Pregnancy is a vulnerable period for women, with an increased risk of mental health issues such as depression and anxiety. The perinatal period is particularly important, as maternal mental health significantly impacts maternal physical health, pregnancy outcomes, postnatal outcomes, and fetal and infant development. Psychotherapeutic interventions for depression are essential,...

DOI: 10.2196/75630 Full text Depression Humans Pregnancy complications Mental health +6

Synergistic effects of capsaicin and ketamine on the depression-like behaviors of animals subjected to the chronic unpredictable mild stress protocol.

Physiology & Behavior October 1, 2025 Irving Aguilar-Martínez, J. Góngora-Alfaro, R. Navarro-Polanco et al.

A significant percentage of depression patients are resistant to pharmacological treatments, highlighting the need for novel antidepressant strategies. Ketamine, an NMDA receptor antagonist, produces rapid antidepressant effects and is effective in treatment-resistant cases, but its association with cognitive and behavioral abnormalities resembling schizophrenia limits broader clinical utility....

DOI: 10.1016/j.physbeh.2025.115122

Efficacy and safety of ketamine maintenance therapy in treatment-resistant depression: A systematic review of treatment protocols and clinical outcomes.

Journal of Affective Disorders October 1, 2025 A. M. Al-Garni, Gustavo Vazquez, Tariq Alotibi et al.

INTRODUCTION Treatment-resistant depression (TRD) represents a significant therapeutic challenge, as conventional treatments demonstrate limited efficacy. Although ketamine's acute antidepressant effects are well-documented, the role of maintenance therapy remains understudied. We conducted a systematic review to assess the efficacy, safety, and optimal implementation strategies of ketamine...

DOI: 10.1016/j.jad.2025.120475

Experteninterview zum Thema psychedelisch unterstützte Psychotherapie (PAP) bei Patienten mit behandlungsresistenter Depression (TRD)

Psychotherapie-Wissenschaft October 1, 2025 Jean Schulthess Watt

Eine Gruppe von Patienten, die schlecht auf Psychotherapie und Medikamente ansprechen, sind Patienten mit der Diagnose einer behandlungsresistenten Depression (TRD). Ein relativ neuer und erfolgreicher Psychotherapieansatz, der auch an der Psychiatrischen Klinik Münsterlingen unter der Leitung von Dr. Krähenmann (Ärztlicher Direktor der Psychiatrischen Dienste Thurgau) umgesetzt wird, ist das...

DOI: 10.30820/1664-9583-2025-2-23

Methodological considerations for interpreting ketamine-naltrexone trials in depression

The International Journal of Neuropsychopharmacology October 1, 2025 Igor D. Bandeira, Luke A. Jelen, Jason M Tucciarone et al. 4 citations

Igor D Bandeira, MD, PhD, Luke A Jelen, MD, PhD, Jason M Tucciarone, MD, PhD, Boris D Heifets, MD, PhD, Carolyn I Rodriguez, MD, PhD, Alan F Schatzberg, MD

DOI: 10.1093/ijnp/pyaf073 Full text Depression economics Medline Clinical trial Clinical neurology +1

Mindfulness-Based Intervention Improves Depression, Anxiety, and Quality of Life in Unstably-Housed Women with PTSD and Substance Use Disorder

Mindfulness October 1, 2025 Dana Rose Garfin, Cordelia Lee, Branislav Jovanovic et al.

Abstract Objective This study sought to evaluate the efficacy of Mindfulness-based Stress Reduction (MBSR) on symptoms of posttraumatic stress, depression, anxiety, and perceived stress and quality of life in unstably-housed women undergoing substance use disorder (SUD) treatment. Despite the potential for MBSR to be a helpful adjunct to ongoing care, prior research on the benefit of MBSR in...

DOI: 10.1007/s12671-025-02661-1

Altered neural reward activation predicts clinical depression improvement after a novel loving-kindness meditation: a multimodal neuroimaging study.

Psychiatry Research Neuroimaging October 1, 2025 Zhaohua Chen, Chun Cui, Xiaoxiao Sun et al.

Major depressive disorder (MDD) has become the second largest risk factor affecting human health, with a progress in its treatment especially non-pharmacological therapies. The loving-kindness meditation (LKM) has been introduced to depression but is not popular due to requirement on awareness and concentration, and its utilization in clinical MDD is absent as well as exploration on neural...

DOI: 10.1016/j.pscychresns.2025.112059 Full text FMRI Reward card-guessing task

Esketamine in a Patient With Major Depressive Disorder and Polysubstance Use: A Case Report.

Cureus October 1, 2025 Abdelazim Ali, Nahida Ahmed, Sona Varghese

Major depressive disorder (MDD) frequently co-occurs with substance use disorders (SUDs), leading to poorer outcomes and limited options. Esketamine is approved for treatment-resistant depression (TRD); its effects on craving and abstinence in SUD are less explored. A 41-year-old man with recurrent MDD (suicidal ideation) and polysubstance use (daily morphine/prescription opioids; intermittent...

DOI: 10.7759/cureus.93876 Full text Treatment-resistant depression Clinical case report Craving reduction Esketamine intranasal +3

Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 1, 2025 Marta L.c. Palhas, Rémi Corne, Raymond Mongeau 4 citations

After years of restrictions due to concerns about their potentially harmful effects, research on psychedelics has entered a new era. Increasing attention has been directed toward their immense therapeutic potential, particularly for psychiatric disorders. Pre-clinical and clinical studies have consistently demonstrated that psychedelic treatments produce therapeutic effects within hours of...

DOI: 10.1016/j.pnpbp.2025.111533 Neuroplasticity Addiction Serotonergic Synaptogenesis +10

Subanesthetic ketamine alters EEG signal complexity: Implications for treatment stratification in depression.

Journal of Affective Disorders October 1, 2025 Weng-Lam Chan, Sebastian Olbrich, Xinwen Jiang et al. 3 citations

Major depressive disorder, particularly its treatment-resistant form (TRD), poses significant treatment challenges. Ketamine, an N-methyl-d-aspartate receptor antagonist, has shown promise in rapidly alleviating depressive symptoms by influencing neuroplasticity and glutamatergic modulation, which are thought to influence brain activity complexity. In this placebo-controlled study, we examined...

DOI: 10.1016/j.jad.2025.119477 Full text Mdd Lempel-ziv complexity Treatment response Depression treatment +4